Actelion Company Profile (OTCMKTS:ALIOF)

About Actelion (OTCMKTS:ALIOF)

Actelion logoActelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:ALIOF
  • CUSIP: N/A
  • Web: www.actelion.com
Capitalization:
  • Market Cap: $29.14 billion
  • Outstanding Shares: 104,638,000
Average Prices:
  • 50 Day Moving Avg: $280.30
  • 200 Day Moving Avg: $260.56
  • 52 Week Range: $138.01 - $286.30
P/E:
  • Trailing P/E Ratio: 40.59
  • Foreward P/E Ratio: 31.97
  • P/E Growth: 2.61
Sales & Book Value:
  • Annual Revenue: $2.54 billion
  • Price / Sales: 11.47
  • Book Value: $15.84 per share
  • Price / Book: 17.58
Dividend:
  • Dividend Yield: 0.8%
Profitability:
  • EBIDTA: $945.69 million
  • Net Margins: 28.89%
  • Return on Equity: 53.21%
  • Return on Assets: 35.24%
Debt:
  • Current Ratio: 2.76%
  • Quick Ratio: 2.51%
Misc:
  • Average Volume: 647 shs.
  • Beta: 1.52
 

Frequently Asked Questions for Actelion (OTCMKTS:ALIOF)

What is Actelion's stock symbol?

Actelion trades on the OTCMKTS under the ticker symbol "ALIOF."

How were Actelion's earnings last quarter?

Actelion Ltd. (OTCMKTS:ALIOF) posted its earnings results on Monday, February, 16th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.09 by $0.22. The business had revenue of $501.50 million for the quarter, compared to the consensus estimate of $546.30 million. Actelion had a return on equity of 53.21% and a net margin of 28.89%. View Actelion's Earnings History.

Who are some of Actelion's key competitors?

Who are Actelion's key executives?

Actelion's management team includes the folowing people:

  • Jean-Pierre Garnier Ph.D., Chairman of the Board of Directors
  • Jean-Paul Clozel, Chief Executive Officer, Member of the Executive Committee, Delegate of the Board of Directors
  • Thomas Widman, Co-Founder
  • Andre C. Muller, Chief Financial Officer, Executive Vice President, Member of the Executive Committee
  • Otto Schwarz, Chief Operating Officer, Executive Vice President, Member of the Executive Committee
  • Guy Braunstein, Executive Vice President, Head of Global Clinical Development, Member of the Executive Committee
  • Nicholas Franco, Executive Vice President, Chief Business Development Officer, Member of the Executive Committee
  • Martine Clozel, Senior Vice President, Chief Scientific Officer, Head of Drug Discovery, Pharmacology & Preclinical Development, Member of the Extended Actelion Executive Committee
  • Marian Borovsky, Senior Vice President, Group General Counsel, Member of the Extended Actelion Executive Committee, Corporate Secretary to the Board of Directors
  • Christian Albrich, Senior Vice President, Head Global Human Resources, Member of the Extended Actelion Executive Committee

How do I buy Actelion stock?

Shares of Actelion can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Actelion's stock price today?

One share of Actelion stock can currently be purchased for approximately $278.50.


MarketBeat Community Rating for Actelion (OTCMKTS ALIOF)
Community Ranking:  1.9 out of 5 ()
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  82
MarketBeat's community ratings are surveys of what our community members think about Actelion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Actelion (OTCMKTS:ALIOF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: N/A

Analysts' Ratings History for Actelion (OTCMKTS:ALIOF)
Show:
DateFirmActionRatingPrice TargetDetails
3/8/2017J P Morgan Chase & CoUpgradeNeutral -> OverweightView Rating Details
1/5/2017Jefferies Group LLCDowngradeBuy -> HoldView Rating Details
(Data available from 6/28/2015 forward)

Earnings

Earnings History for Actelion (OTCMKTS:ALIOF)
Earnings by Quarter for Actelion (OTCMKTS:ALIOF)
Earnings History by Quarter for Actelion (OTCMKTS ALIOF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/20/2016Q3 2016$2.12$2.39$603.47 million$626.61 millionViewN/AView Earnings Details
10/20/2015Q3 2015$1.61$1.90$527.94 million$533.07 millionViewN/AView Earnings Details
4/21/2015Q1 2015$1.28$1.68$506.91 million$539.65 millionViewN/AView Earnings Details
2/16/2015Q4 2014$1.09$0.87$546.30 million$501.50 millionViewN/AView Earnings Details
10/21/2014Q3 2014$1.50$1.61$511.25 million$525.03 millionViewN/AView Earnings Details
7/22/2014Q2 2014$1.37$2.00$516.67 million$583.43 millionViewN/AView Earnings Details
4/17/2014Q1 2014$1.12$1.65$504.04 million$531.17 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Actelion (OTCMKTS:ALIOF)
Current Year EPS Consensus Estimate: $7.76 EPS
Next Year EPS Consensus Estimate: $8.71 EPS

Dividends

Dividend History for Actelion (OTCMKTS:ALIOF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Actelion (OTCMKTS:ALIOF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Actelion (OTCMKTS:ALIOF)
Latest Headlines for Actelion (OTCMKTS:ALIOF)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Actelion Ltd. : June 19, 2017
finance.yahoo.com - June 19 at 3:30 PM
finance.yahoo.com logoActelion spin-off Idorsia's shares rise 30 pct in market debut
finance.yahoo.com - June 16 at 4:05 PM
finance.yahoo.com logoActelion Ltd. :ALIOF-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 4:05 PM
finance.yahoo.com logoActelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : June 15, 2017
finance.yahoo.com - June 15 at 5:02 PM
finance.yahoo.com logoJohnson & Johnson Stock Just Hit an All-Time High: Here's Why It Could Go Higher
finance.yahoo.com - June 11 at 3:27 PM
finance.yahoo.com logoJohnson & Johnson Moves Forward with Actelion Purchase After EU Approval
finance.yahoo.com - June 9 at 3:41 PM
finance.yahoo.com logoActelion Ltd. – Value Analysis (US OTC:ALIOF) : May 2, 2017
finance.yahoo.com - May 3 at 8:11 AM
finance.yahoo.com logoActelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : May 1, 2017
finance.yahoo.com - May 1 at 9:44 AM
nasdaq.com logoJanssen Holding Acquires 92.51% Of Actelion
www.nasdaq.com - April 25 at 3:26 PM
finance.yahoo.com logoHere's Why Risk-Averse Investors May Want to Think Twice About Buying Johnson & Johnson
finance.yahoo.com - April 25 at 3:26 PM
nasdaq.com logoJohnson & Johnson Announces Interim Result For Actelion Tender Offer
www.nasdaq.com - March 31 at 1:54 AM
finance.yahoo.com logoJ&J declares Actelion tender offer a success, sees closing in Q2
finance.yahoo.com - March 31 at 1:54 AM
finance.yahoo.com logoJ&J declares Actelion tender offer a success, sees closing in second quarter
finance.yahoo.com - March 31 at 1:54 AM
americanbankingnews.com logoActelion Ltd (ALIOF) Raised to Overweight at JPMorgan Chase & Co.
www.americanbankingnews.com - March 8 at 12:35 PM
finance.yahoo.com logoUnited Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
finance.yahoo.com - February 23 at 3:28 PM
rttnews.com logoActelion FY16 Profit Rises
www.rttnews.com - February 14 at 1:56 AM
fool.com logoJust 2 of the 13 Largest Drugmakers Have More Cash Than Debt -- Can You Guess Who They Are?
www.fool.com - February 8 at 3:37 PM
fool.com logoJohnson & Johnson May Never Recoup Its Costs to Buy Actelion
www.fool.com - February 4 at 1:41 AM
finance.yahoo.com logoJ&J to Acquire Actelion for $30B: Is It a Strategic Fit?
finance.yahoo.com - January 27 at 3:35 PM
nasdaq.com logoJohnson & Johnson To Buy Actelion For $30 Bln With Spin-out Of New R&D Company
www.nasdaq.com - January 26 at 8:45 PM
rttnews.com logoActelion Stock Up On $30 Bln Takeover Deal With JNJ; To Spin-Out R&D To New Firm
www.rttnews.com - January 26 at 8:45 PM
us.rd.yahoo.com logo[$$] J&J/Actelion: high pressure sale
us.rd.yahoo.com - January 26 at 3:43 PM
ft.com logo[$$] Johnson & Johnson to buy Swiss biotech company Actelion for $30bn
www.ft.com - January 26 at 3:43 PM
ft.com logo[$$] J&J digs deep to claim its $30bn Actelion prize
www.ft.com - January 26 at 3:43 PM
investorplace.com logoJohnson & Johnson (JNJ) Stock Could Win BIG After Actelion Purchase
investorplace.com - January 26 at 12:15 PM
bloomberg.com logoActelion Founder's $1.5 Billion Payday Gives Him Shot at More - Bloomberg
www.bloomberg.com - January 26 at 12:11 PM
marketwatch.com logoEurope Markets: European stocks hang at 1-year high, buoyed by Actelion and bank shares
www.marketwatch.com - January 26 at 6:05 AM
bloomberg.com logoJ&J Seals $30 Billion Actelion Deal to Enter Rare Disease Arena - Bloomberg
www.bloomberg.com - January 26 at 4:39 AM
ft.com logo[$$] Novartis: buying time
www.ft.com - January 25 at 3:32 PM
thestreet.com logoJohnson & Johnson CEO Talks Trump, Taxes and M&A After Mixed Earnings
us.rd.yahoo.com - January 24 at 8:49 PM
finance.yahoo.com logoJ&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit
finance.yahoo.com - January 24 at 3:48 PM
ft.com logo[$$] J&J disappoints on 2017 forecasts due to strong dollar
www.ft.com - January 24 at 3:48 PM
thestreet.com logoJohnson & Johnson CEO Talks Trump, M&A After Mixed Earnings
www.thestreet.com - January 24 at 3:48 PM
finance.yahoo.com logo5 Best Performing Healthcare Mutual Funds of 2016
finance.yahoo.com - January 23 at 3:29 PM
zacks.com logoVIVUS Licenses Rights to PAH Drugs from Selten Pharma
www.zacks.com - January 11 at 3:45 PM
finance.yahoo.com logo4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
finance.yahoo.com - January 10 at 3:29 PM
finance.yahoo.com logoUnited Therapeutics' PAH Suite Bodes Well, Competition Rife
finance.yahoo.com - December 29 at 3:29 PM
finance.yahoo.com logoJ&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?
finance.yahoo.com - December 22 at 3:26 PM
ft.com logo[$$] Actelion/J&J: hypertension tactics
www.ft.com - December 22 at 3:26 PM
feeds.benzinga.com logoWall Street's M&A Chatter From December 21
feeds.benzinga.com - December 22 at 7:27 AM
ft.com logo[$$] Johnson & Johnson and Actelion disclose 'exclusive' deal talks
www.ft.com - December 21 at 4:28 PM
thestreet.com logoEuropean Stocks Drift Lower; Dollar Dominates Global Financial Markets
us.rd.yahoo.com - December 16 at 3:33 PM
thestreet.com logo5 Things You Must Know Before the Market Opens Friday
us.rd.yahoo.com - December 16 at 3:33 PM
publicnow.com logoActelion receives positive CHMP opinion for chlormethine gel (Ledaga) for the treatment of MF-CTCL
us.rd.yahoo.com - December 16 at 3:33 PM
thestreet.com logoJohnson & Johnson Looks for New Deal That's Just Right
us.rd.yahoo.com - December 15 at 3:52 PM
thestreet.com logoActelion's Independent Streak Gives Rise to Doubt That Sanofi Will Fill the Breach
us.rd.yahoo.com - December 14 at 8:43 PM
us.rd.yahoo.com logo[$$] Actelion: PAH, humbug
us.rd.yahoo.com - December 14 at 8:43 PM
nasdaq.com logoJ&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?
www.nasdaq.com - December 14 at 3:39 PM
ft.com logo[$$] Sanofi in talks to acquire biotech Actelion as J&J bows out
www.ft.com - December 14 at 1:31 AM
thestreet.com logoActelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNP
www.thestreet.com - December 7 at 4:06 PM

Social

Chart

Actelion (ALIOF) Chart for Wednesday, June, 28, 2017

This page was last updated on 6/28/2017 by MarketBeat.com Staff